Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Lymphoma

  Free Subscription


Articles published in Bone Marrow Transplant

Retrieve available abstracts of 131 articles:
HTML format



Single Articles


    July 2021
  1. LEW TE, Cliff ERS, Dickinson M, Tam CS, et al
    T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease.
    Bone Marrow Transplant. 2021 Jul 20. pii: 10.1038/s41409-021-01418.
    PubMed    


  2. LOWENBERG B, Kersten MJ, Gale RP, van Oers M, et al
    Professor Anton Hagenbeek 1948-2021: Father of MRD and lymphoma expert.
    Bone Marrow Transplant. 2021 Jul 19. pii: 10.1038/s41409-021-01375.
    PubMed    


  3. CORTELAZZO S, Mian M, Evangelista A, Devizzi L, et al
    Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term.
    Bone Marrow Transplant. 2021 Jul 7. pii: 10.1038/s41409-021-01391.
    PubMed    


    June 2021
  4. GEVA M, Pryce A, Shouval R, Fein JA, et al
    High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2021 Jun 29. pii: 10.1038/s41409-021-01377.
    PubMed     Abstract available


    May 2021
  5. VIJENTHIRA A, Kuruvilla J, Prica A
    Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy.
    Bone Marrow Transplant. 2021 May 13. pii: 10.1038/s41409-021-01327.
    PubMed     Abstract available


  6. DERENZINI E, Tabanelli V, Sammassimo S, Mazzara S, et al
    Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma.
    Bone Marrow Transplant. 2021 May 7. pii: 10.1038/s41409-021-01320.
    PubMed    


    April 2021
  7. TOYODA K, Yasunaga JI, Choi I, Suehiro Y, et al
    The HTLV-1 proviral status is a potential prognostic biomarker for adult T-cell leukemia-lymphoma treated with allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2021 Apr 29. pii: 10.1038/s41409-021-01311.
    PubMed    


  8. EYRE TA, Caillard S, Finel H, Boumendil A, et al
    Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT.
    Bone Marrow Transplant. 2021 Apr 16. pii: 10.1038/s41409-021-01270.
    PubMed     Abstract available


  9. SHAPIRO LC, Mustafa J, Lombardo A, Khatun F, et al
    Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population.
    Bone Marrow Transplant. 2021 Apr 12. pii: 10.1038/s41409-021-01280.
    PubMed    


    March 2021
  10. BENTO L, Gutierrez A, Novelli S, Montoro J, et al
    Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study.
    Bone Marrow Transplant. 2021 Mar 25. pii: 10.1038/s41409-021-01264.
    PubMed     Abstract available


  11. IMOTO H, Yoshioka S, Hiramoto N, Morita-Fujita M, et al
    Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for systemic Epstein-Barr virus-positive T-cell lymphoma of childhood.
    Bone Marrow Transplant. 2021 Mar 10. pii: 10.1038/s41409-021-01263.
    PubMed    


  12. TESSOULIN B, Chiron D, Thieblemont C, Oberic L, et al
    Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial.
    Bone Marrow Transplant. 2021 Mar 3. pii: 10.1038/s41409-020-01198.
    PubMed     Abstract available


  13. PYTLIK R, Vackova B, Konirova E, Trnkova M, et al
    Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT.
    Bone Marrow Transplant. 2021;56:709-712.
    PubMed    


    February 2021
  14. PRINCE HM, Abeyakoon C
    Allogeneic haematopoietic stem cell transplantation for advanced stage mycosis fungoides and Sezary syndrome: never-late, never-never?
    Bone Marrow Transplant. 2021 Feb 1. pii: 10.1038/s41409-020-01150.
    PubMed    


    January 2021
  15. SAKURAI M, Mori T, Kato K, Kanaya M, et al
    Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation.
    Bone Marrow Transplant. 2021 Jan 29. pii: 10.1038/s41409-020-01192.
    PubMed    


  16. PETTENGELL R, Uddin R, Boumendil A, Johnson R, et al
    Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial.
    Bone Marrow Transplant. 2021 Jan 15. pii: 10.1038/s41409-020-01182.
    PubMed     Abstract available


  17. DOMINGO-DOMENECH E, Duarte RF, Boumedil A, Onida F, et al
    Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sezary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2021 Jan 8. pii: 10.1038/s41409-020-01197.
    PubMed     Abstract available


    December 2020
  18. MONTORO J, Chorao P, Bento L, Cabrero M, et al
    Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors.
    Bone Marrow Transplant. 2020 Dec 12. pii: 10.1038/s41409-020-01161.
    PubMed    


  19. SONG GY, Yoon DH, Suh C, Moon JH, et al
    Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma.
    Bone Marrow Transplant. 2020 Dec 4. pii: 10.1038/s41409-020-01160.
    PubMed     Abstract available


  20. DANYLESKO I, Shouval R, Shem-Tov N, Yerushalmi R, et al
    Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma.
    Bone Marrow Transplant. 2020 Dec 3. pii: 10.1038/s41409-020-01156.
    PubMed     Abstract available


    November 2020
  21. CASTAGNA L, Pagliardini T, Bramanti S, Schiano de Colella JM, et al
    Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome.
    Bone Marrow Transplant. 2020 Nov 15. pii: 10.1038/s41409-020-01133.
    PubMed     Abstract available


  22. GHAFOURI S, Timmerman J, Larson S, Mead MD, et al
    Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?
    Bone Marrow Transplant. 2020 Nov 10. pii: 10.1038/s41409-020-01099.
    PubMed    


  23. BERSVENDSEN HS, Haugnes HS, Dahl AA, Fagerli UM, et al
    Sexual dysfunction is prevalent in female lymphoma survivors after autologous stem-cell transplantation and is associated with younger age, chronic fatigue, and mental distress.
    Bone Marrow Transplant. 2020 Nov 3. pii: 10.1038/s41409-020-01098.
    PubMed     Abstract available


    October 2020
  24. BENTO L, Boumendil A, Finel H, Khvedelidze I, et al
    Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party-EBMT.
    Bone Marrow Transplant. 2020 Oct 12. pii: 10.1038/s41409-020-01075.
    PubMed     Abstract available


    September 2020
  25. KELSEY P, Pearce R, Perry J, Kirkland K, et al
    Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma-a retrospective study from the BSBMT (BEAM versus LEAM).
    Bone Marrow Transplant. 2020 Sep 29. pii: 10.1038/s41409-020-01071.
    PubMed    


    August 2020
  26. MURANUSHI H, Shindo T, Hishizawa M, Tokunaga M, et al
    Correction: GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2020 Aug 25. pii: 10.1038/s41409-020-01037.
    PubMed     Abstract available


  27. BADAR T, Johnson BD, Hamadani M
    Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.
    Bone Marrow Transplant. 2020 Aug 11. pii: 10.1038/s41409-020-01029.
    PubMed    


  28. ALLRED J, Bharucha K, Ozutemiz C, He F, et al
    Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations.
    Bone Marrow Transplant. 2020 Aug 6. pii: 10.1038/s41409-020-01018.
    PubMed    


    July 2020
  29. GALLI E, Allain V, Di Blasi R, Bernard S, et al
    G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma.
    Bone Marrow Transplant. 2020 Jul 27. pii: 10.1038/s41409-020-01006.
    PubMed    


  30. MURANUSHI H, Shindo T, Hishizawa M, Tokunaga M, et al
    GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2020 Jul 14. pii: 10.1038/s41409-020-00996.
    PubMed     Abstract available


  31. CIUREA SO, Kongtim P, Srour S, Saini N, et al
    Can we cure refractory Hodgkin's lymphoma with transplantation?
    Bone Marrow Transplant. 2020 Jul 7. pii: 10.1038/s41409-020-0989.
    PubMed    


    June 2020
  32. SELBERG L, Stadtherr P, Dietrich S, Tran TH, et al
    The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis.
    Bone Marrow Transplant. 2020 Jun 18. pii: 10.1038/s41409-020-0976.
    PubMed     Abstract available


  33. YANG L, Tan Y, Shi J, Zhao Y, et al
    Correction: Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma.
    Bone Marrow Transplant. 2020 Jun 15. pii: 10.1038/s41409-020-0962.
    PubMed     Abstract available


  34. MERLI M, Luminari S, Farina L, Cocito F, et al
    Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi.
    Bone Marrow Transplant. 2020 Jun 15. pii: 10.1038/s41409-020-0967.
    PubMed    


    May 2020
  35. SELLNER L, Schetelig J, Koster L, Choi G, et al
    Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey.
    Bone Marrow Transplant. 2020 May 22. pii: 10.1038/s41409-020-0946.
    PubMed    


  36. SUREDA A, Genadieva Stavrik S, Boumendil A, Finel H, et al
    Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT.
    Bone Marrow Transplant. 2020 May 15. pii: 10.1038/s41409-020-0929.
    PubMed     Abstract available


  37. LIN RJ, Ho C, Devlin SM, Ruiz JD, et al
    Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma.
    Bone Marrow Transplant. 2020 May 13. pii: 10.1038/s41409-020-0942.
    PubMed    


  38. DAMLAJ M, Abuelgasim KA, Alhejazi A, Alahmari B, et al
    Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma.
    Bone Marrow Transplant. 2020 May 13. pii: 10.1038/s41409-020-0935.
    PubMed    


  39. ONISHI A, Inamoto Y, Tajima K, Yamaguchi J, et al
    Detrimental effects of pretransplant cisplatin-based chemotherapy on renal function after allogeneic hematopoietic cell transplantation for lymphoma.
    Bone Marrow Transplant. 2020 May 4. pii: 10.1038/s41409-020-0917.
    PubMed    


    April 2020
  40. DI RENZO N, Musso M, Scime R, Cupri A, et al
    Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantat
    Bone Marrow Transplant. 2020 Apr 28. pii: 10.1038/s41409-020-0909.
    PubMed     Abstract available


  41. MOHTY M, Dulery R, Gauthier J, Malard F, et al
    CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview.
    Bone Marrow Transplant. 2020 Apr 18. pii: 10.1038/s41409-020-0892.
    PubMed     Abstract available


  42. JO JC, Kim JS, Lee JH, Lee JH, et al
    Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL).
    Bone Marrow Transplant. 2020 Apr 17. pii: 10.1038/s41409-020-0908.
    PubMed    


  43. TALLEUR AC, Flerlage JE, Shook DR, Chilsen AM, et al
    Autologous hematopoietic cell transplantation for the treatment of relapsed/refractory pediatric, adolescent, and young adult Hodgkin lymphoma: a single institutional experience.
    Bone Marrow Transplant. 2020 Apr 9. pii: 10.1038/s41409-020-0879.
    PubMed     Abstract available


    March 2020
  44. BASTOS-OREIRO M, Balsalobre P, Miralles P, Berenguer J, et al
    Autologous stem cell transplantation for lymphoma in HIV+ patients: higher rate of infections compared with non-HIV lymphoma.
    Bone Marrow Transplant. 2020 Mar 4. pii: 10.1038/s41409-020-0846.
    PubMed     Abstract available


    January 2020
  45. OTHMAN J, Armytage T, Wong K, Arthur C, et al
    Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma.
    Bone Marrow Transplant. 2020 Jan 20. pii: 10.1038/s41409-020-0789.
    PubMed    


  46. HUESO T, Gastinne T, Garciaz S, Tchernonog E, et al
    Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.
    Bone Marrow Transplant. 2020 Jan 17. pii: 10.1038/s41409-020-0783.
    PubMed     Abstract available


    November 2019
  47. MUSSETTI A, Sureda A
    Is this real life? Is this just fantasy? Decreased relapse following haploidentical transplant in Hodgkin's lymphoma with posttransplant cyclophosphamide.
    Bone Marrow Transplant. 2019 Nov 21. pii: 10.1038/s41409-019-0754.
    PubMed    


  48. BERSVENDSEN HS, Haugnes HS, Dahl AA, Fagerli UM, et al
    Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation.
    Bone Marrow Transplant. 2019 Nov 19. pii: 10.1038/s41409-019-0745.
    PubMed     Abstract available


  49. DOMINGO-DOMENECH E, Boumendil A, Climent F, Sengeloev H, et al
    Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT.
    Bone Marrow Transplant. 2019 Nov 6. pii: 10.1038/s41409-019-0734.
    PubMed     Abstract available


  50. DOMINGO-DOMENECH E, Boumendil A, Climent F, Socie G, et al
    Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2019 Nov 6. pii: 10.1038/s41409-019-0732.
    PubMed     Abstract available


    October 2019
  51. ATOUI A, El Labban M, Ghaoui N, El Darsa H, et al
    Correction: Complete remission of seronegative rheumatoid arthritis following haplo-identical stem cell transplantation for peripheral T-cell lymphoma.
    Bone Marrow Transplant. 2019 Oct 4. pii: 10.1038/s41409-019-0706.
    PubMed     Abstract available


    September 2019
  52. SUREDA A, Chabannon C, Masszi T, Pohlreich D, et al
    Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor.
    Bone Marrow Transplant. 2019 Sep 30. pii: 10.1038/s41409-019-0693.
    PubMed     Abstract available


  53. GONZALEZ-BARCA E, Boumendil A, Blaise D, Trneny M, et al
    Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantati
    Bone Marrow Transplant. 2019 Sep 20. pii: 10.1038/s41409-019-0650.
    PubMed     Abstract available


    August 2019
  54. HERR MM, Torka P, Zhang Y, Wallace PK, et al
    Correction: Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant.
    Bone Marrow Transplant. 2019 Aug 30. pii: 10.1038/s41409-019-0647.
    PubMed     Abstract available


  55. HILL BT, Roberts ZJ, Xue A, Rossi JM, et al
    Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma.
    Bone Marrow Transplant. 2019 Aug 30. pii: 10.1038/s41409-019-0657.
    PubMed    


  56. RIVAS MM, Berro M, Prates MV, Yantorno S, et al
    Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment.
    Bone Marrow Transplant. 2019 Aug 21. pii: 10.1038/s41409-019-0640.
    PubMed     Abstract available


  57. ATOUI A, El Labban M, Ghaoui N, El Darsa H, et al
    Complete remission of seronegative rheumatoid arthritis following haplo-identical stem cell transplantation for peripheral T-cell lymphoma.
    Bone Marrow Transplant. 2019 Aug 12. pii: 10.1038/s41409-019-0635.
    PubMed    


  58. EINSELE H, Rasche L, Topp MS, Martin Kortum K, et al
    The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT.
    Bone Marrow Transplant. 2019;54.
    PubMed     Abstract available


    June 2019
  59. VISANI G, Loscocco F, Bagaloni I, Ruzzo A, et al
    XRCC1 399GG genotype predicts significantly longer overall survival in resistant lymphoma patients treated with Benda-EAM and ASCT.
    Bone Marrow Transplant. 2019 Jun 23. pii: 10.1038/s41409-019-0572.
    PubMed    


  60. HERR MM, Torka P, Zhang Y, Wallace PK, et al
    Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant.
    Bone Marrow Transplant. 2019 Jun 21. pii: 10.1038/s41409-019-0591.
    PubMed     Abstract available


    May 2019
  61. DIETRICH S, Dreger P, Hermine O, Kyriakou C, et al
    Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2019 May 31. pii: 10.1038/s41409-019-0583.
    PubMed     Abstract available


    April 2019
  62. JAIMOVICH G, Ostriz MBR, Castro M, Riera L, et al
    CBeV (cyclophosphamide, bendamustine and etoposide) pre-autotransplant conditioning in persons with lymphoma.
    Bone Marrow Transplant. 2019 Apr 23. pii: 10.1038/s41409-019-0528.
    PubMed    


    March 2019
  63. PREDILETTO I, Farag SA, Bacher U, Jeker B, et al
    High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients.
    Bone Marrow Transplant. 2019 Mar 19. pii: 10.1038/s41409-019-0508.
    PubMed    


  64. HOLDERRIED TAW, Fraccaroli A, Schumacher M, Heine A, et al
    The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma.
    Bone Marrow Transplant. 2019 Mar 4. pii: 10.1038/s41409-019-0498.
    PubMed     Abstract available


    February 2019
  65. KAZUMA Y, Shimazu Y, Hishizawa M, Nishikori M, et al
    Effectiveness of cord blood transplantation for the treatment of refractory angioimmunoblastic T-cell lymphoma: a series of three cases.
    Bone Marrow Transplant. 2019 Feb 26. pii: 10.1038/s41409-019-0494.
    PubMed    


  66. KATO K, Mori T, Kim SW, Sawa M, et al
    Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B-cell lymphoma: Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantati
    Bone Marrow Transplant. 2019 Feb 26. pii: 10.1038/s41409-019-0491.
    PubMed    


  67. HUBEL K, Re A, Boumendil A, Finel H, et al
    Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party.
    Bone Marrow Transplant. 2019 Feb 25. pii: 10.1038/s41409-019-0480.
    PubMed     Abstract available


  68. FARNAULT L, Venton G, Pourroy B, Jourde-Chiche N, et al
    Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen.
    Bone Marrow Transplant. 2019 Feb 4. pii: 10.1038/s41409-019-0467.
    PubMed    


  69. SINGER S, Sharma N, Dean R, Zhao Q, et al
    BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.
    Bone Marrow Transplant. 2019 Feb 4. pii: 10.1038/s41409-019-0463.
    PubMed     Abstract available


    January 2019
  70. ABUELGASIM KA, Alzahrani M, Alsharhan Y, Khairi M, et al
    Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma.
    Bone Marrow Transplant. 2019 Jan 30. pii: 10.1038/s41409-019-0454.
    PubMed    


  71. FUJI S, Yamaguchi T, Inoue Y, Utsunomiya A, et al
    VCAP-AMP-VECP as a preferable induction chemotherapy in transplant-eligible patients with aggressive adult T-cell leukemia-lymphoma: a propensity score analysis.
    Bone Marrow Transplant. 2019 Jan 21. pii: 10.1038/s41409-019-0446.
    PubMed     Abstract available


  72. ABADIR E, Bryant C, Larsen S, Clark GJ, et al
    Targeting the niche: depleting haemopoietic stem cells with targeted therapy.
    Bone Marrow Transplant. 2019 Jan 21. pii: 10.1038/s41409-019-0445.
    PubMed     Abstract available


    December 2018
  73. JIN A, Feng J, Wang Z, Jiang L, et al
    Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy.
    Bone Marrow Transplant. 2018 Dec 18. pii: 10.1038/s41409-018-0412.
    PubMed     Abstract available


  74. YOSHIMITSU M, Utsunomiya A, Fuji S, Fujiwara H, et al
    A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma.
    Bone Marrow Transplant. 2018 Dec 13. pii: 10.1038/s41409-018-0400.
    PubMed     Abstract available


    November 2018
  75. WULF G, Hasenkamp J, Jung W, Wilhelm C, et al
    Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease.
    Bone Marrow Transplant. 2018 Nov 9. pii: 10.1038/s41409-018-0360.
    PubMed     Abstract available


  76. SAKELLARI I, Gavriilaki E, Bouziana S, Constantinou V, et al
    BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2018 Nov 8. pii: 10.1038/s41409-018-0395.
    PubMed    


  77. NORMAN JE, Schouten HC, Dreger P, Robinson SP, et al
    The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies.
    Bone Marrow Transplant. 2018 Nov 2. pii: 10.1038/s41409-018-0372.
    PubMed     Abstract available


  78. DAHI PB, Lazarus HM, Sauter CS, Giralt SA, et al
    Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma.
    Bone Marrow Transplant. 2018 Nov 2. pii: 10.1038/s41409-018-0378.
    PubMed     Abstract available


    October 2018
  79. KALOYANNIDIS P, Shaibani EA, Apostolidis I, Kanfar S, et al
    Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease.
    Bone Marrow Transplant. 2018 Oct 18. pii: 10.1038/s41409-018-0362.
    PubMed    


  80. DE LA HOZ A, Foolad F, Gallegos C, Kornblau S, et al
    Nivolumab-induced encephalitis post allogeneic stem cell transplant in a patient with Hodgkin's disease.
    Bone Marrow Transplant. 2018 Oct 15. pii: 10.1038/s41409-018-0363.
    PubMed    


  81. DOS SANTOS KB, Costa LJM, Bettarello G, da Matta Abreu M, et al
    LEAM versus CBV for conditioning in autologous hematopoietic stem cell transplantation for lymphoma.
    Bone Marrow Transplant. 2018 Oct 3. pii: 10.1038/s41409-018-0349.
    PubMed    


    August 2018
  82. TSANG ES, Villa D, Loscocco F, Visani G, et al
    High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Bone Marrow Transplant. 2018 Aug 31. pii: 10.1038/s41409-018-0328.
    PubMed    


  83. KUNO M, Ito A, Tanaka T, Inamoto Y, et al
    Severe immune-related complications early after allogeneic hematopoietic cell transplantation for nivolumab-pretreated lymphoma.
    Bone Marrow Transplant. 2018 Aug 21. pii: 10.1038/s41409-018-0310.
    PubMed    


  84. PICCALUGA PP, Rapezzi D, Gazzola A, Malagola M, et al
    Resolving the diagnostic dilemma of T-cell clonal expansion after hematopoietic stem cell transplantation in T-cell lymphoma patients by TCR-gamma next generation sequencing.
    Bone Marrow Transplant. 2018 Aug 16. pii: 10.1038/s41409-018-0268.
    PubMed    


  85. PHILLIPS EH, Lannon MM, Lopes A, Chadwick H, et al
    High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study.
    Bone Marrow Transplant. 2018 Aug 13. pii: 10.1038/s41409-018-0294.
    PubMed    


    July 2018
  86. HIRANO M, Jimbo K, Ogawa M, Ochi K, et al
    Chronic inflammatory demyelinating polyneuropathy in adult T-cell leukemia-lymphoma patients following allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2018 Jul 23. pii: 10.1038/s41409-018-0202.
    PubMed    


    June 2018
  87. FUJI S, Inoue Y, Utsunomiya A, Moriuchi Y, et al
    Impact of pretransplant central nervous system invasion in patients with aggressive adult T-cell leukemia lymphoma.
    Bone Marrow Transplant. 2018 Jun 13. pii: 10.1038/s41409-018-0248.
    PubMed    


  88. KURUVILLA J, Tzeng CH, Cho SG, Kim SJ, et al
    A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing </=70 kg.
    Bone Marrow Transplant. 2018 Jun 12. pii: 10.1038/s41409-018-0253.
    PubMed     Abstract available


  89. BEKADJA MA, Talhi S, Amani K, Osmani S, et al
    Outcomes of modified-eam conditioned autologous non-cryopreserved hematopoietic sct for lymphoma. A retrospective single-centre study.
    Bone Marrow Transplant. 2018 Jun 12. pii: 10.1038/s41409-018-0243.
    PubMed    


  90. ROBINSON SP, Boumendil A, Finel H, Dreger P, et al
    High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party.
    Bone Marrow Transplant. 2018 Jun 8. pii: 10.1038/s41409-018-0196.
    PubMed     Abstract available


    May 2018
  91. AVIGDOR A, Shouval R, Jacoby E, Davidson T, et al
    CAR T cells induce a complete response in refractory Burkitt Lymphoma.
    Bone Marrow Transplant. 2018 May 24. pii: 10.1038/s41409-018-0235.
    PubMed    


  92. FUJI S, Kurosawa S, Inamoto Y, Murata T, et al
    Decision analysis of up-front autologous hematopoietic stem cell transplantation in patients with peripheral T-cell lymphoma.
    Bone Marrow Transplant. 2018 May 24. pii: 10.1038/s41409-018-0223.
    PubMed    


  93. HUBEL K, Ostermann H, Glass B, Noppeney R, et al
    Plerixafor in non-Hodgkin's lymphoma patients: a German analysis of time, effort and costs.
    Bone Marrow Transplant. 2018 May 24. pii: 10.1038/s41409-018-0228.
    PubMed     Abstract available


  94. SUREDA A, Dreger P, Bishop MR, Kroger N, et al
    Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies.
    Bone Marrow Transplant. 2018 May 24. pii: 10.1038/s41409-018-0214.
    PubMed     Abstract available


  95. DREGER P, Michallet M, Bosman P, Dietrich S, et al
    Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
    Bone Marrow Transplant. 2018 May 4. pii: 10.1038/s41409-018-0207.
    PubMed     Abstract available


    April 2018
  96. YANG L, Tan Y, Shi J, Zhao Y, et al
    Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma.
    Bone Marrow Transplant. 2018 Apr 30. pii: 10.1038/s41409-018-0184.
    PubMed    


  97. BROWNBACK KR, Pitts LR, Abhyankar S
    Safety of nintedanib for treatment of fibrotic lung disease after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2018 Apr 26. pii: 10.1038/s41409-018-0182.
    PubMed    


    March 2018
  98. NAITHANI R, Dayal N, Pathak S, Rai R, et al
    Hematopoietic stem cell transplantation using non-cryopreserved peripheral blood stem cells graft is effective in multiple myeloma and lymphoma.
    Bone Marrow Transplant. 2018 Mar 29. pii: 10.1038/s41409-018-0174.
    PubMed    


  99. INOUE Y, Fuji S, Tanosaki R, Inamoto Y, et al
    Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma.
    Bone Marrow Transplant. 2018 Mar 9. pii: 10.1038/s41409-018-0139.
    PubMed     Abstract available


    February 2018
  100. AVIVI I, Boumendil A, Finel H, Nagler A, et al
    Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2018 Feb 20. pii: 10.1038/s41409-017-0063.
    PubMed     Abstract available


  101. MARCHESI F, Capria S, Giannarelli D, Trisolini SM, et al
    BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant.
    Bone Marrow Transplant. 2018 Feb 13. pii: 10.1038/s41409-018-0120.
    PubMed    


  102. HSU YT, Tsai HJ, Chang JS, Li SS, et al
    Stem cell transplantation for T-cell lymphomas in Taiwan.
    Bone Marrow Transplant. 2018 Feb 12. pii: 10.1038/s41409-018-0116.
    PubMed     Abstract available


  103. CASTAGNA L, Boubdallah R, Furst S, Coso D, et al
    Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT.
    Bone Marrow Transplant. 2018;53:234.
    PubMed     Abstract available


    January 2018
  104. FUJI S, Kurosawa S, Inamoto Y, Murata T, et al
    Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis.
    Bone Marrow Transplant. 2018 Jan 25. pii: 10.1038/s41409-017-0082.
    PubMed    


  105. JIMENEZ-UBIETO A, Grande C, Caballero D, Yanez L, et al
    Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry.
    Bone Marrow Transplant. 2018 Jan 23. pii: 10.1038/s41409-018-0096.
    PubMed    


  106. LAHOUD OB, Moskowitz AJ, Horwitz SM, Giralt SA, et al
    Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma.
    Bone Marrow Transplant. 2018 Jan 22. pii: 10.1038/s41409-017-0086.
    PubMed    


  107. ROBINSON SP, Boumendil A, Finel H, Peggs KS, et al
    Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party.
    Bone Marrow Transplant. 2018 Jan 15. pii: 10.1038/s41409-017-0067.
    PubMed     Abstract available


  108. GAUTHIER J, Poire X, Gac AC, Leclerc M, et al
    Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0018.
    PubMed     Abstract available


    December 2017
  109. FALCONE U, Jiang H, Bashir S, Tsang R, et al
    Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma.
    Bone Marrow Transplant. 2017 Dec 21. pii: 10.1038/s41409-017-0054.
    PubMed    


  110. MARIOTTI J, Bramanti S, Devillier R, Furst S, et al
    Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma.
    Bone Marrow Transplant. 2017 Dec 21. pii: 10.1038/s41409-017-0032.
    PubMed    


  111. MOHTY M, Azar N, Chabannon C, Le Gouill S, et al
    Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.
    Bone Marrow Transplant. 2017 Dec 18. pii: 10.1038/s41409-017-0033.
    PubMed     Abstract available


    October 2017
  112. JOFFE E, Rosenberg D, Rozovski U, Perry C, et al
    Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma.
    Bone Marrow Transplant. 2017 Oct 16. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


  113. KANSAGRA A, Inwards DJ, Ansell SM, Micallef IN, et al
    Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation.
    Bone Marrow Transplant. 2017 Oct 16. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


  114. RE A, Gini G, Rupolo M, Levis A, et al
    Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk.
    Bone Marrow Transplant. 2017 Oct 9. doi: 10.1038/bmt.2017.
    PubMed    


  115. GALIENI P, Troiani E, Bigazzi C, Mazzotta S, et al
    Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2017 Oct 2. doi: 10.1038/bmt.2017.
    PubMed    


  116. RIEDELL PA, Bishop MR
    Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.
    Bone Marrow Transplant. 2017 Oct 2. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


    August 2017
  117. FREEMAN AT, Stover AM, Grover NS, Shea TC, et al
    Patient perspectives on physical function after allogeneic hematopoietic stem cell transplantation: a qualitative study.
    Bone Marrow Transplant. 2017 Aug 7. doi: 10.1038/bmt.2017.
    PubMed    


    July 2017
  118. DAMLAJ M, Ghazi S, Syed G, Pasha T, et al
    Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma.
    Bone Marrow Transplant. 2017 Jul 10. doi: 10.1038/bmt.2017.
    PubMed    


    June 2017
  119. KASSAM S, Chernucha E, O'Neill A, Hemmaway C, et al
    High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


  120. GIACCONE L, Festuccia M, Zallio F, Sorasio R, et al
    Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed    


    May 2017
  121. BENTO L, Boumendil A, Finel H, Le Gouill S, et al
    Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.
    Bone Marrow Transplant. 2017 May 22. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


  122. CASTAGNA L, Bramanti S, Devillier R, Sarina B, et al
    Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.
    Bone Marrow Transplant. 2017;52:797.
    PubMed    


    April 2017
  123. SCHORB E, Fox CP, Fritsch K, Isbell L, et al
    High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.
    Bone Marrow Transplant. 2017 Apr 24. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


  124. EL CHEIKH J, Massoud R, Abudalle I, Haffar B, et al
    Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma.
    Bone Marrow Transplant. 2017 Apr 10. doi: 10.1038/bmt.2017.
    PubMed    


  125. YAMASAKI S, Suzuki R, Hatano K, Fukushima K, et al
    Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed     Abstract available


  126. GARNIER A, Guillaume T, Peterlin P, Bene MC, et al
    Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed    


    February 2017
  127. BOURLON C, Alamoudi S, Kumar D, Viswabandya A, et al
    A short tale of blood, kidney and brain: BK virus encephalitis in an allogeneic stem cell transplant recipient.
    Bone Marrow Transplant. 2017 Feb 20. doi: 10.1038/bmt.2017.
    PubMed    


    January 2017
  128. MCDUFFEE E, Aue G, Cook L, Ramos-Delgado C, et al
    Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed    


    October 2016
  129. GAUTHIER J, Holmberg L, Wu D, Bensinger W, et al
    Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas.
    Bone Marrow Transplant. 2016 Oct 24. doi: 10.1038/bmt.2016.
    PubMed    


    September 2016
  130. BAI L, Peters L, Xia W, Best G, et al
    Assessing pilot vial material as a surrogate for functional and phenotypic stem cell markers in cryopreserved haematopoietic stem cell product.
    Bone Marrow Transplant. 2016 Sep 26. doi: 10.1038/bmt.2016.
    PubMed    


    July 2016
  131. EHRLICH KB, Miller GE, Scheide T, Baveja S, et al
    Pre-transplant emotional support is associated with longer survival after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2016 Jul 18. doi: 10.1038/bmt.2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: